- Joined
- Jun 2, 2007
- Messages
- 56
***
Supply Chain Restrictions (BIOSECURE Act) The BIOSECURE Act, taking effect throughout 2026, restricts U.S. entities from sourcing biotechnology equipment or services from specific "companies of concern" (primarily in China). This has forced importers to migrate their supply chains to FDA-registered and inspected facilities to maintain compliance.
Automated Border Seizures (Import Alert 66-80) The FDA established the "Green List" specifically for GLP-1 APIs (like semaglutide and tirzepatide). Customs and Border Protection (CBP) now utilizes "Detention Without Physical Examination" (DWPE), meaning any shipment from a manufacturer NOT on the Green List is automatically seized at the border without the need for a physical lab test.
Closure of the "Research Only" Loophole The FDA and DOJ now aggressively apply the "Intended Use Doctrine." Labeling imports as "Research Use Only" (RUO) or "Not for Human Consumption" no longer serves as a legal shield. If a vendor's digital footprint includes dosing guides or therapeutic claims, the FDA treats the shipment as an unapproved new drug, leading to immediate seizure and potential misbranding charges.
Elimination of Compounding Categories By early 2026, the FDA moved several popular peptides (such as BPC-157 and Thymosin Beta-4) into a prohibited status for compounding. Because these substances no longer qualify for legal compounding under Section 503A, importing their bulk powders now carries a significant risk of criminal enforcement for distributing unapproved substances.
Supply Chain Restrictions (BIOSECURE Act) The BIOSECURE Act, taking effect throughout 2026, restricts U.S. entities from sourcing biotechnology equipment or services from specific "companies of concern" (primarily in China). This has forced importers to migrate their supply chains to FDA-registered and inspected facilities to maintain compliance.
Automated Border Seizures (Import Alert 66-80) The FDA established the "Green List" specifically for GLP-1 APIs (like semaglutide and tirzepatide). Customs and Border Protection (CBP) now utilizes "Detention Without Physical Examination" (DWPE), meaning any shipment from a manufacturer NOT on the Green List is automatically seized at the border without the need for a physical lab test.
Closure of the "Research Only" Loophole The FDA and DOJ now aggressively apply the "Intended Use Doctrine." Labeling imports as "Research Use Only" (RUO) or "Not for Human Consumption" no longer serves as a legal shield. If a vendor's digital footprint includes dosing guides or therapeutic claims, the FDA treats the shipment as an unapproved new drug, leading to immediate seizure and potential misbranding charges.
Elimination of Compounding Categories By early 2026, the FDA moved several popular peptides (such as BPC-157 and Thymosin Beta-4) into a prohibited status for compounding. Because these substances no longer qualify for legal compounding under Section 503A, importing their bulk powders now carries a significant risk of criminal enforcement for distributing unapproved substances.















































































